Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Dyadic International Inc

Healthcare US DYAI

0.76USD
-0.0359(4.51%)

Last update at 2026-06-16T18:07:00Z

Day Range

0.760.81
LowHigh

52 Week Range

0.651.35
LowHigh

Fundamentals

  • Previous Close 0.80
  • Market Cap30.48M
  • Volume81013
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM3.09M
  • Revenue Per Share TTM0.10
  • Gross Profit TTM 0.77M
  • Diluted EPS TTM-0.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.36463M -5.80916M -6.79546M -9.73526M -13.07025M
Minority interest - - - - -
Net income -7.36463M -5.80916M -6.79546M -9.37088M -12.92165M
Selling general administrative 5.76M 6.13M 5.82M 6.42M 6.70M
Selling and marketing expenses - - - - -
Gross profit 0.77M 2.30M 0.92M 0.81M 0.46M
Reconciled depreciation - - - - -
Ebit - -11.25945M -8.19132M -10.11576M -14.72749M
Ebitda -7.14592M -5.38119M -8.15291M -10.06584M -16.13923M
Depreciation and amortization - 5.88M 0.04M 0.05M -1.41175M
Non operating income net other - - - - -
Operating income -7.14592M -5.90082M -8.22974M -10.11576M -14.72749M
Other operating expenses 10.28M 9.40M 11.13M 13.05M 17.03M
Interest expense 0.46M 0.43M 0.00000M -0.38050M 0.05M
Tax provision - - - - 0.00000M
Interest income 0.28M 0.46M 0.42M 0.18M 0.05M
Net interest income -0.17181M 0.03M 0.42M 0.18M 0.05M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -5.80916M -8.19132M -0.36437M -0.14860M
Total revenue 3.09M 3.50M 2.90M 2.93M 2.40M
Total operating expenses 7.92M 8.20M 9.15M 10.92M 15.09M
Cost of revenue 2.32M 1.19M 1.98M 2.12M 1.94M
Total other income expense net -0.21871M 0.09M 1.43M 0.38M 1.66M
Discontinued operations - - - - -
Net income from continuing ops -7.36463M -5.80916M -6.79546M -9.73526M -13.07025M
Net income applicable to common shares - - - -9.73526M -13.07025M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.95M 9.93M 8.22M 13.71M 21.30M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.45M 0.33M 0.33M 0.39M 0.38M
Total liab 8.71M 7.46M 2.34M 2.63M 2.91M
Total stockholder equity 1.23M 2.47M 5.88M 11.09M 18.39M
Deferred long term liab - - - - -
Other current liab 2.80M 1.91M 1.14M 1.00M 0.86M
Common stock 0.05M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.05M 0.04M 0.04M 0.04M 0.04M
Retained earnings -93.45111M -86.08648M -80.27732M -73.48186M -63.74660M
Other liab - - - 0.18M 0.35M
Good will - - - - -
Other assets - - - 0.00605M 0.00612M
Cash 4.62M 6.51M 6.52M 5.79M 15.75M
Cash and equivalents - - - - -
Total current liabilities 3.69M 2.45M 2.25M 2.45M 2.56M
Current deferred revenue - - 0.49M 0.18M 0.15M
Net debt 0.44M -1.44053M -6.37810M -5.79427M -15.74848M
Short term debt 0.03M 0.05M 0.05M - -
Short long term debt - - - - -
Short long term debt total 5.06M 5.07M 0.14M - -
Other stockholder equity 94.64M 88.51M 86.11M 84.53M 82.10M
Property plant equipment - - - - -
Total current assets 9.90M 9.83M 8.07M 13.42M 21.01M
Long term investments - - 0.00000M 0.28M 0.28M
Net tangible assets - - - 11.09M 18.39M
Short term investments 2.70M 2.76M 0.75M 6.85M 4.51M
Net receivables 1.13M 0.24M 0.48M 0.39M 0.37M
Long term debt 5.03M 4.98M - - -
Inventory - - 0.00000M - -
Accounts payable 0.85M 0.48M 0.58M 1.28M 1.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M 0.01M 0.01M 0.00605M 0.00612M
Deferred long term asset charges - - - - -
Non current assets total 0.05M 0.10M 0.15M 0.29M 0.29M
Capital lease obligations 0.03M 0.09M 0.14M - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.08M -1.87625M 7.45M -2.36928M 5.22M
Change to liabilities - - - -0.50559M 1.08M
Total cashflows from investing activities 0.08M -1.87625M 7.45M -2.36928M 5.22M
Net borrowings 0.00000M 5.82M 0.00000M - -
Total cash from financing activities 4.96M 5.85M 0.00000M 0.54M 1.23M
Change to operating activities - - - 0.27M 0.14M
Net income -7.36463M -5.80916M -6.79546M -9.73526M -13.07025M
Change in cash -0.65325M -0.00828M 0.72M -9.95421M -4.88856M
Begin period cash flow 6.51M 6.52M 5.79M 15.75M 20.64M
End period cash flow 5.85M 6.51M 6.52M 5.79M 15.75M
Total cash from operating activities -5.70222M -3.97481M -6.72675M -8.08377M -11.27694M
Issuance of capital stock 4.94M 0.00000M - - -
Depreciation -0.02417M -0.07106M -0.05303M 0.03M 0.33M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - 0.14M
Change to account receivables -0.85784M 0.21M -0.09313M -0.08327M -0.03179M
Sale purchase of stock - - - - -
Other cashflows from financing activities 4.96M 0.02M 7.45M 0.54M 1.23M
Change to netincome - - - 1.97M 0.61M
Capital expenditures 0.00000M 0.00000M 0.00001M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.66M 0.75M -0.14321M -0.32117M 1.19M
Stock based compensation 0.93M 1.13M 1.24M 1.89M 1.78M
Other non cash items 0.10M -0.04645M -1.03221M 0.05M -1.17903M
Free cash flow -5.70222M -3.97481M -6.72675M -8.08377M -11.27694M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DYAI
Dyadic International Inc		 -0.0359 4.51% 0.76 - 15.82 9.86 24.73 22.90 -2.9344
NVO
Novo Nordisk A/S		 -0.165 0.38% 43.76 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.0012 0.0027% 44.87 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.21 0.49% 452.67 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.57 0.09% 615.55 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International Inc

1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094

Key Executives

Name Title Year Born
Mr. Mark A. Emalfarb Founder, CEO, Pres & Director 1956
Ms. Ping Wang Rawson CPA, M.B.A. Chief Financial Officer 1976
Mr. Joseph P. Hazelton Chief Bus. Officer NA
Dr. Ronen Tchelet Ph.D. VP of Research & Bus. Devel. 1958
Ms. Ana Gómez Rodriguez Sec. of the Board NA
Mr. Mark A. Emalfarb Founder, CEO, President & Director 1956
Mr. Joseph P. Hazelton Chief Business Officer NA
Mr. Doug Pace B.A. Executive Vice President of Business Development NA
Ms. Ana Gómez Rodriguez Secretary of the Board NA
Mr. Mark A. Emalfarb Founder, CEO & Director 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions